Page last updated: 2024-08-23

bromocriptine and Atherosclerotic Parkinsonism

bromocriptine has been researched along with Atherosclerotic Parkinsonism in 47 studies

Research

Studies (47)

Timeframe	Studies, this research(%)	All Research%
pre-1990	23 (48.94)	18.7374
1990's	20 (42.55)	18.2507
2000's	2 (4.26)	29.6817
2010's	2 (4.26)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dunnett, SB; Lane, EL; Lelos, MJ; Murphy, EM; O'Neill, MJ	1
Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F	1
Cortesi, R; Drechsler, M; Esposito, E; Fantin, M; Lain, F; Mariani, P; Marti, M; Menegatti, E; Morari, M; Paccamiccio, L; Sivieri, E	1
Lustig, A; Moscovici, M; Ringwald, E; Spiegel, R; Vamos, E	1
Azorin, JM; Bouchacourt, M; Giudicelli, S; Lavergne, T	1
Angelini, L; Broggi, G; Mainini, P; Moretti, G; Nardocci, N	1
Danielczyk, W	1
Bertha, G; Lechner, H; Ott, E	1
Ogawa, N	1
Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA	1
Fukuda, T; Irifune, M; Nomoto, M	1
Bédard, PJ; Boucher, R; Di Paolo, T; Gagnon, C; Gomez-Mancilla, B; Markstein, R	1
Bédard, PJ; Di Paolo, T; Gagnon, C; Gomez-Mancilla, B; Markstein, R	1
Akiyama, K; Ishihara, T; Kashihara, K; Shiro, Y; Shohmori, T	1
Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E	1
de Saint-Martin, A; Hirsch, E; Marescaux, C; Picard, F; Salmon, E	1
Banerji, T; Jenner, P; Marsden, CD; Pearce, RK	1
Brotchie, JM; Crossman, AR; Henry, B	2
Kuno, S; Mizuta, E; Yoshida, O; Yoshimura, N	1
Haida, M; Kozuma, R; Shinohara, Y; Takagi, S; Takahashi, W; Yoshii, F	1
Adair, JC; Davis, LE	1
Andersson, M; Cenci, MA; Kirik, D; Lundblad, M; Wierup, N; Winkler, C	1
Battista, AF; Goldstein, M; Hata, F; Lew, JY; Lieberman, A	1
Halbhübner, K; Herken, H; Loos, D	1
Battista, AF; Goldstein, M; Lew, JY; Lieberman, A; Matsumoto, Y	1
Caine, ED; Davis, GC; Ebert, MH; Kopin, IJ; Markey, SP; Reichert, CM; Williams, AC	1
Durand, JP; Gautier, JC	1
Albizzati, MG; Frattola, L; Scarlato, G; Trabucchi, M	1
Ulm, G; Völler, GW	1
Barreca, T; Gallamini, A; Gianrossi, R; Nizzo, MC; Queirolo, A	1
Silverman, PB	1
De Pooter, MC; De Reuck, J; Godefroy, O; Leys, D; Petit, H	1
Bédard, PJ; Di Paolo, T; Rouillard, C	1
Bakheit, AM; Henderson, LM; Moore, AP; Simpson, JA; Thomas, M	1
Benna, P; Bergamasco, B; Scarzella, L	1
Bar, M; Graff, E; Isakov, M; Oberman, Z; Rabey, JM; Scharf, M	1
Bédard, P; Boucher, R; Daigle, M; Di Paolo, T	1
Dick, P; Schulz, P	1
Donovan, K; Fahn, S; Gross, J; Sczesni, B; Truong, DD; van Bakel, A; Wiley, MK	1
Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB	1
Perquin, WV; Van Leeuwen, RB	1
Bédard, PJ; Boucher, R; Di Paolo, T; Falardeau, P	1
Williams, A	1
Kadykov, AS; Pivovarova, VM; Shvedkov, VV; Stoliarova, LG	1
Jonsson, G; Mefford, I; Schultz, W; Studer, A; Sundström, E	1
Ito, H; Kameyama, M; Kase, M; Kuroiwa, Y; Mizuno, Y; Nakanishi, T; Narabayashi, H; Sobue, I; Toyokura, Y; Uono, M	1

Reviews

1 review(s) available for bromocriptine and Atherosclerotic Parkinsonism

Article	Year
Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. European neurology, 1994, Volume: 34 Suppl 3 Topics: Animals; Brain; Bromocriptine; Corpus Striatum; Dopamine Agonists; Free Radicals; Humans; Levodopa; Mice; Parkinson Disease; Parkinson Disease, Secondary; Premedication; Reactive Oxygen Species; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission	1994

Article

Year

Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages.

European neurology, 1994, Volume: 34 Suppl 3

Topics: Animals; Brain; Bromocriptine; Corpus Striatum; Dopamine Agonists; Free Radicals; Humans; Levodopa; Mice; Parkinson Disease; Parkinson Disease, Secondary; Premedication; Reactive Oxygen Species; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission

1994

Trials

4 trial(s) available for bromocriptine and Atherosclerotic Parkinsonism

Article	Year
Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome. Acta endocrinologica. Supplementum, 1978, Volume: 216 Topics: Animals; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Ergot Alkaloids; Haplorhini; Humans; Levodopa; Parkinson Disease, Secondary; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine	1978
[Treatment of parkinsonian syndromes by bromocriptin]. La Nouvelle presse medicale, 1977, Jan-22, Volume: 6, Issue:3 Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Hypotension; Levodopa; Male; Movement Disorders; Nausea; Parkinson Disease, Secondary	1977
Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease. Interim results. European neurology, 1990, Volume: 30, Issue:2 Topics: Bromocriptine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary	1990
Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study. Acta neurologica Scandinavica, 1985, Volume: 72, Issue:2 Topics: Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary	1985

Other Studies

42 other study(ies) available for bromocriptine and Atherosclerotic Parkinsonism

Article	Year
Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat. Neuroreport, 2013, Dec-18, Volume: 24, Issue:18 Topics: Animals; Antiparkinson Agents; Bromocriptine; Conditioning, Operant; Dopamine Agonists; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Reaction Time	2013
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. Bioscience, biotechnology, and biochemistry, 2013, Volume: 77, Issue:2 Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine Agonists; Food, Formulated; Levodopa; Magnesium; Magnesium Deficiency; Male; Mice; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase	2013
Solid lipid nanoparticles as delivery systems for bromocriptine. Pharmaceutical research, 2008, Volume: 25, Issue:7 Topics: Absorptiometry, Photon; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Chromatography, High Pressure Liquid; Cryoelectron Microscopy; Dialysis; Drug Delivery Systems; Kinetics; Light; Lipids; Male; Microscopy, Electron; Nanoparticles; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Scattering, Radiation; Spectrophotometry, Ultraviolet; Triglycerides; X-Ray Diffraction	2008
[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)]. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1980, Volume: 13, Issue:6 Topics: Adult; Antipsychotic Agents; Bromocriptine; Chlorpromazine; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Prolactin; Schizophrenia	1980
[Neuroleptic malignant syndrome. Efficacy of bromocriptine]. Presse medicale (Paris, France : 1983), 1984, Jun-30, Volume: 13, Issue:27 Topics: Antipsychotic Agents; Bromocriptine; Catatonia; Humans; Male; Middle Aged; Parkinson Disease, Secondary	1984
A perplexing case of juvenile extrapyramidal disease. Italian journal of neurological sciences, 1981, Volume: 2, Issue:2 Topics: Adolescent; Atrophy; Basal Ganglia Diseases; Bromocriptine; Electroencephalography; Female; Globus Pallidus; Humans; Levodopa; Parkinson Disease, Secondary; Tomography, X-Ray Computed	1981
[Crises in the course of Parkinson's disease]. Wiener medizinische Wochenschrift (1946), 1980, Feb-29, Volume: 130, Issue:4 Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotic Disorders	1980
[Current treatment of Parkinsonian syndrome]. Die Medizinische Welt, 1980, Volume: 31, Issue:40 Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease, Secondary	1980
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes	1994
Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets. European journal of pharmacology, 1993, Jul-20, Volume: 238, Issue:2-3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azepines; Bromocriptine; Callithrix; Dopamine Agents; Female; Injections, Intravenous; Male; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine D2	1993
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Homovanillic Acid; Indoles; Locomotion; Macaca fascicularis; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Phenanthridines; Psychomotor Performance; Receptors, Dopamine; Receptors, Dopamine D1	1993
Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Progress in neuro-psychopharmacology & biological psychiatry, 1995, Volume: 19, Issue:4 Topics: Animals; Autoradiography; Behavior, Animal; Brain Chemistry; Bromocriptine; Dopamine Agents; Dopamine Agonists; Female; Indoles; Macaca fascicularis; MPTP Poisoning; Neostriatum; Ovariectomy; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2	1995
Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat. Life sciences, 1996, Volume: 58, Issue:10 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Base Sequence; Behavior, Animal; Bromocriptine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine; Dopamine Agonists; Levodopa; Male; Molecular Sequence Data; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Transcription Factor AP-1	1996
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide	1995
Postencephalitic stereotyped involuntary movements responsive to L-Dopa. Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:5 Topics: Adult; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Encephalitis; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D2; Stereotyped Behavior; Tomography, X-Ray Computed; Trihexyphenidyl	1996
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D2	1998
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental neurology, 1998, Volume: 151, Issue:2 Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine	1998
Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 286, Issue:1 Topics: Animals; Bromocriptine; Dopamine Agonists; Ergolines; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reflex; Triazoles; Urinary Bladder; Urination	1998
Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. Journal of the neurological sciences, 1998, Sep-18, Volume: 160, Issue:1 Topics: Basal Ganglia; Bromocriptine; Carbon Monoxide Poisoning; Carbon Radioisotopes; Caudate Nucleus; Cerebral Hemorrhage; Combined Modality Therapy; Convalescence; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Globus Pallidus; Humans; Hyperbaric Oxygenation; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nerve Tissue Proteins; Parkinson Disease, Secondary; Psychomotor Performance; Putamen; Receptors, Dopamine D2; Spiperone; Tomography, Emission-Computed	1998
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental neurology, 1999, Volume: 155, Issue:2 Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger	1999
Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:3 Topics: Adult; Antiparkinson Agents; Brain Edema; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Methanol; Parkinson Disease, Secondary; Putamen; Tomography, X-Ray Computed	1999
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. The European journal of neuroscience, 2002, Volume: 15, Issue:1 Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Sympatholytics	2002
Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors. Pharmacology, 1978, Volume: 16 Suppl 1 Topics: Animals; Antiparkinson Agents; Bromocriptine; Chlorocebus aethiops; Drug Evaluation; Drug Evaluation, Preclinical; Ergot Alkaloids; Haplorhini; Models, Biological; Parkinson Disease, Secondary; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Receptors, Dopamine; Synaptosomes; Tyrosine 3-Monooxygenase	1978
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs. Arzneimittel-Forschung, 1978, Volume: 28, Issue:10 Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; Central Nervous System Diseases; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Electromyography; Gluconates; Levodopa; Lisuride; Male; Motor Neurons; Muscle Contraction; Niacinamide; Parkinson Disease, Secondary; Rats; Reserpine; RNA; Spinal Cord; Sugar Phosphates	1978
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry research, 1979, Volume: 1, Issue:3 Topics: Adult; Bromocriptine; Carbidopa; Chronic Disease; Humans; Levodopa; Locus Coeruleus; Male; Meperidine; Opioid-Related Disorders; Parkinson Disease, Secondary; Substantia Nigra	1979
Hemiparkinsonism. A human model for studying dopaminergic supersensitivity. Archives of neurology, 1979, Volume: 36, Issue:4 Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Dextroamphetamine; Disease Models, Animal; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease, Secondary; Receptors, Dopamine	1979
[Bromocriptin in Parkinson's syndrome]. Die Medizinische Welt, 1979, Dec-22, Volume: 30, Issue:51-52 Topics: Adult; Aged; Bromocriptine; Encephalitis; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary	1979
[Endocrine effects of bromocryptin in patients with Parkinsonism]. Bollettino della Societa italiana di biologia sperimentale, 1976, Oct-15, Volume: 52, Issue:19 Topics: Aged; Bromocriptine; Ergolines; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Pituitary Hormones	1976
Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat. European journal of pharmacology, 1992, Dec-15, Volume: 229, Issue:2-3 Topics: Animals; Benzazepines; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra	1992
[Parkinsonian syndrome caused by carbon monoxide poisoning. Preliminary results of the treatment with bromocriptine]. Revue neurologique, 1991, Volume: 147, Issue:5 Topics: Adult; Aged; Bromocriptine; Carbon Monoxide Poisoning; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Time Factors	1991
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. European journal of pharmacology, 1990, Aug-28, Volume: 185, Issue:2-3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Brain; Brain Chemistry; Bromocriptine; Dopamine; Female; Homovanillic Acid; Kinetics; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine; Spiperone	1990
Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta neurologica Scandinavica, 1990, Volume: 81, Issue:5 Topics: Aged; Bromocriptine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease, Secondary	1990
Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease. Acta neurologica Scandinavica, 1990, Volume: 81, Issue:5 Topics: Administration, Oral; Aged; Amantadine; Biperiden; Bromocriptine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Piperidines	1990
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Brain research, 1986, Aug-06, Volume: 379, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Bromocriptine; Catecholamines; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Prolactin; Pyridines	1986
Therapeutic rounds: neuroleptic malignant syndrome. Clinical therapeutics, 1986, Volume: 8, Issue:6 Topics: Adult; Antipsychotic Agents; Bromocriptine; Catatonia; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary	1986
[Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases]. Der Nervenarzt, 1988, Volume: 59, Issue:2 Topics: Adult; Aged; Antipsychotic Agents; Brain; Bromocriptine; Dantrolene; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary; Receptors, Dopamine; Schizophrenia	1988
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. Neurology, 1986, Volume: 36, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; Drug Administration Schedule; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra; Time Factors	1986
Bromocriptine therapy in striatonigral degeneration. Journal of neurology, neurosurgery, and psychiatry, 1988, Volume: 51, Issue:4 Topics: Aged; Bromocriptine; Humans; Levodopa; Male; Nerve Degeneration; Parkinson Disease, Secondary; Putamen; Substantia Nigra	1988
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain research, 1986, Aug-06, Volume: 379, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors	1986
MPTP toxicity: clinical features. Journal of neural transmission. Supplementum, 1986, Volume: 20 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Bromocriptine; California; Chemical Industry; District of Columbia; Female; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease, Secondary; Pyridines	1986
[Experience with the use of parlodel in the treatment of Parkinson patients]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1986, Volume: 86, Issue:2 Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Hypoxia, Brain; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary	1986
Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Neuroscience letters, 1985, Aug-30, Volume: 59, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain Chemistry; Bromocriptine; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Movement; Parkinson Disease, Secondary; Pyridines	1985